Breaking News Instant updates and real-time market news.

LGND

Ligand

$97.32

-1.22 (-1.24%)

07:58
10/10/16
10/10
07:58
10/10/16
07:58

Ligand price target raised to $154 after Carnexiv approval at Roth Capital

Roth Capital analyst Joseph Pantginis raised his price target on Ligand to $154 from $150 after partner Lundbeck announced that the FDA approved Carnexiv injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types. Ligand will receive a $1.25M milestone payment this quarter and is entitled to receive a 2.75% royalty on sales of the drug, noted Pantginis, who keeps a Buy rating on Ligand shares.

LGND Ligand
$97.32

-1.22 (-1.24%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
09/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Hold from Underperform at Jefferies with analyst Jason Gammel citing valuation and improving financial metrics. 2. DineEquity (DIN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Chris O'Cull saying the stock has reached a good entry point, while its risk/reward ratio is "compelling." 3. Gaming and Leisure Properties (GLPI) upgraded to Overweight at Morgan Stanley. 4. Aviva (AV) upgraded to Buy from Neutral at UBS with the firm saying the company is positioned to be the risk-adjusted dividend leader in the sector. 5. Ligand (LGND) upgraded to Hold from Sell at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
HCWC
10/05/16
NO CHANGE
Target $160
HCWC
Buy
Ligand price target raised to $160 from $146 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Ligand Pharmaceuticals to $160 citing three recent positive events, namely positive Phase II focal segmental glomerulosclerosis data from partner Retrophin, the beginning of a Phase II clinical trial with LGD-6972 for the treatment of type 2 diabetes and the licensing of several therapeutic programs to Seelos. Werther keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

IVC

Invacare

$13.25

0.2 (1.53%)

16:42
04/27/17
04/27
16:42
04/27/17
16:42
Hot Stocks
Invacare reports completion of consent decree milestones »

Invacare reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 18

    May

VCRA

Vocera

$24.96

0.42 (1.71%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Vocera sees Q2 adjusted EPS (8c)-(3c), consensus 2c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Benefitfocus sees FY17 EPS (37c)-(24c), consensus (31c) »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

VCRA

Vocera

$24.96

0.42 (1.71%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Vocera cuts FY17 adjusted EPS view to 2c-19c from 7c-24c, consensus 19c »

Backs FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

SSNC

SS&C

$37.65

0.34 (0.91%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
SS&C sees FY17 adjusted revenue $1.66B-$1.69B, consensus $1.67B »

Reports FY17 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

VCRA

Vocera

$24.96

0.42 (1.71%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Earnings
Vocera reports Q1 adjusted EPS (5c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Earnings
Benefitfocus sees Q2 EPS (16c)-(13c), consensus (13c) »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

IRET

Investors Real Estate

$6.07

-0.09 (-1.46%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Hot Stocks
Investors Real Estate announces CEO, senior management changes »

IRET, in a continuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$37.65

0.34 (0.91%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
SS&C sees Q2 adjusted revenue $408M-$416M, consensus $412.69M »

Sees Q2 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

MSTR

MicroStrategy

$192.49

-0.52 (-0.27%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
MicroStrategy reports Q1 GAAP EPS $1.28, may not compare to consensus $1.47 »

Reports Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

ECOL

US Ecology

$48.45

-0.25 (-0.51%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
US Ecology backs FY17 EPS $1.69-$1.93, consensus $1.79 »

"Overall, business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

SSNC

SS&C

$37.65

0.34 (0.91%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
SS&C reports Q1 adjusted EPS 44c, consensus 44c »

Reports Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

INVA

Innoviva

$12.59

-0.26 (-2.02%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Innoviva reports Q1 adjusted EPS 19c, consensus 26c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Benefitfocus reports Q1 EPS (11c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Sarepta raises FY17 revenue from above $80M to above $95M, consensus $97.78M »

"Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOL

US Ecology

$48.45

-0.25 (-0.51%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Earnings
US Ecology reports Q1 EPS 24c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Hot Stocks
Alphabet Class A shares rise 5% to $935 after earnings beat »

Alphabet Class A shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

, LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Hot Stocks
Air Liquide to sell welding unit to Lincoln Electric France »

Air Liquide (AIQUY)…

AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

16:37
04/27/17
04/27
16:37
04/27/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 4/17 Money Supply…

16:36
04/27/17
04/27
16:36
04/27/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 4/26 Fed Balance…

RMD

ResMed

$72.85

1.1 (1.53%)

16:36
04/27/17
04/27
16:36
04/27/17
16:36
Earnings
ResMed reports Q3 non-GAAP EPS 71c, consensus 71c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

HEP

Holly Energy

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Holly Energy raises quarterly distribution 7.8% to 62c per unit »

The board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BIDU

Baidu

$187.86

1.19 (0.64%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Baidu reports 451,000 active online marketing customers in Q1 »

Representing a 23.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MOBL

MobileIron

$4.45

-0.05 (-1.11%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Earnings
Breaking Earnings news story on MobileIron »

MobileIron backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    Jun

LPLA

LPL Financial

$38.52

-0.84 (-2.13%)

16:35
04/27/17
04/27
16:35
04/27/17
16:35
Hot Stocks
Breaking Hot Stocks news story on LPL Financial »

LPL Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.